Antibody specificities and effect of meningococcal carriage in icelandic teenagers receiving the Norwegian serogroup B outer membrane vesicle vaccine
- PMID: 12819059
- PMCID: PMC162037
- DOI: 10.1128/IAI.71.7.3775-3781.2003
Antibody specificities and effect of meningococcal carriage in icelandic teenagers receiving the Norwegian serogroup B outer membrane vesicle vaccine
Abstract
Antibody specificities of pre- and postvaccination serum samples from 40 (53%) teenagers who received three doses of the Norwegian Neisseria meningitidis serogroup B vaccine (B:15:P1.7,16) during a previous trial in Iceland (Perkins et al., J. Infect. Dis. 177:683-691, 1998) were analyzed with serum bactericidal activity (SBA) and immunoblotting assays with reference and isogenic meningococcal H44/76 vaccine strains. The H44/76 variants demonstrated significant vaccine-induced SBA to P1.7,16 PorA and Opc but not to PorB, Opa5.5, and a heterologous PorA protein. On blots, immunoglobulin G levels to all these proteins increased significantly after vaccination. Measurement of SBA to the two main variable regions (P1.7 and P1.16) on the P1.7,16 PorA with PorA deletion mutants revealed significantly higher activity to the P1.7,- and P1.-,16 mutants compared to the P1.7,16 strain, indicating exposure of new accessible epitopes. Only 12 (30%) serum samples showed distinct decreases with these or the P1.-,- mutant, with most samples containing SBA to the P1.7 and P1.16 combination. In contrast, P1.16-specific antibodies were mainly found on blots. Thirteen of the vaccinees (32.5%) were carriers of meningococci at the time of the third dose, of whom four (30.8%) harbored strains of the ET-5 complex. Carriage of P1.15 strains was generally reflected in > or =4-fold increases in SBA and distinct immunoglobulin G binding to the P1.19,15 PorA on blots. Although vaccination did not elicit bactericidal activity to the serotype 15 PorB, most carriers of serotype 15 strains showed > or =4-fold increases in SBA to this antigen.
Figures

Similar articles
-
Cross-reactivity of antibodies against PorA after vaccination with a meningococcal B outer membrane vesicle vaccine.Infect Immun. 2003 Apr;71(4):1650-5. doi: 10.1128/IAI.71.4.1650-1655.2003. Infect Immun. 2003. PMID: 12654777 Free PMC article. Clinical Trial.
-
Specificity of human bactericidal antibodies against PorA P1.7,16 induced with a hexavalent meningococcal outer membrane vesicle vaccine.Infect Immun. 1996 Jul;64(7):2745-51. doi: 10.1128/iai.64.7.2745-2751.1996. Infect Immun. 1996. PMID: 8698504 Free PMC article. Clinical Trial.
-
A Meningococcal Outer Membrane Vesicle Vaccine with Overexpressed Mutant FHbp Elicits Higher Protective Antibody Responses in Infant Rhesus Macaques than a Licensed Serogroup B Vaccine.mBio. 2019 Jun 18;10(3):e01231-19. doi: 10.1128/mBio.01231-19. mBio. 2019. PMID: 31213564 Free PMC article.
-
The VR2 epitope on the PorA P1.7-2,4 protein is the major target for the immune response elicited by the strain-specific group B meningococcal vaccine MeNZB.Clin Vaccine Immunol. 2006 Apr;13(4):486-91. doi: 10.1128/CVI.13.4.486-491.2006. Clin Vaccine Immunol. 2006. PMID: 16603616 Free PMC article.
-
Development and characterisation of outer membrane vesicle vaccines against serogroup A Neisseria meningitidis.Vaccine. 2005 May 31;23(29):3762-74. doi: 10.1016/j.vaccine.2005.02.021. Epub 2005 Mar 14. Vaccine. 2005. PMID: 15893613
Cited by
-
Comparison and correlation of neisseria meningitidis serogroup B immunologic assay results and human antibody responses following three doses of the Norwegian meningococcal outer membrane vesicle vaccine MenBvac.Infect Immun. 2006 Aug;74(8):4557-65. doi: 10.1128/IAI.00466-06. Infect Immun. 2006. PMID: 16861642 Free PMC article. Clinical Trial.
-
Outer membrane vesicles as a platform for the discovery of antibodies to bacterial pathogens.Appl Microbiol Biotechnol. 2024 Feb 24;108(1):232. doi: 10.1007/s00253-024-13033-5. Appl Microbiol Biotechnol. 2024. PMID: 38396192 Free PMC article. Review.
-
Novel blocking human IgG directed against the pentapeptide repeat motifs of Neisseria meningitidis Lip/H.8 and Laz lipoproteins.J Immunol. 2011 Apr 15;186(8):4881-94. doi: 10.4049/jimmunol.1003623. Epub 2011 Mar 14. J Immunol. 2011. PMID: 21402895 Free PMC article.
-
Stability of PorA during a meningococcal disease epidemic.J Clin Microbiol. 2005 Feb;43(2):832-7. doi: 10.1128/JCM.43.2.832-837.2005. J Clin Microbiol. 2005. PMID: 15695688 Free PMC article.
-
A novel meningococcal outer membrane vesicle vaccine with constitutive expression of FetA: A phase I clinical trial.J Infect. 2015 Sep;71(3):326-37. doi: 10.1016/j.jinf.2015.05.006. Epub 2015 May 15. J Infect. 2015. PMID: 25982025 Free PMC article. Clinical Trial.
References
-
- Bash, M. C., F. Lynn, N. F. Concepcion, J. W. Tappero, G. M. Carlone, and C. E. Frasch. 2000. Genetic and immunological characterization of a novel serotype 4,15 strain of Neisseria meningitidis. FEMS Immunol. Med. Microbiol. 29:169-176. - PubMed
-
- Bjune, G., E. A. Høiby, J. K. Grønnesby, O. Arnesen, J. H. Fredriksen, A. Halstensen, E. Holten, A.-K. Lindbak, H. Nøkleby, E. Rosenqvist, L. K. Solberg, O. Closs, J. Eng, L. O. Frøholm, A. Lystad, L. S. Bakketeig, and B. Hareide. 1991. Effect of an outer membrane vesicle vaccine against group B meningococcal disease in Norway. Lancet 338:1093-1096. - PubMed
-
- Boslego, J., J. Garcia, C. Cruz, W. Zollinger, B. Brandt, S. Ruiz, M. Martinez, J. Arthur, P. Underwood, W. Silva, E. Moran, W. Hankins, J. Gilly, J. Mays, and the Chilean National Committee for Meningococcal Disease. 1995. Efficacy, safety, and immunogenicity of a meningococcal group B (15:P1.3) outer membrane protein vaccine in Iquique, Chile. Vaccine 13:821-829. - PubMed
-
- Caugant, D. A., P. Bol, E. A. Høiby, H. C. Zanen, and L. O. Frøholm. 1990. Clones of serogroup B Neisseria meningitidis causing systemic disease in the Netherlands 1958 through 1986. J. Infect. Dis. 162:867-874. - PubMed
-
- Delvig, A. A., E. Wedege, D. A. Caugant, R. Dalseg, J. Kolberg, A. Achtman, and E. Rosenqvist. 1995. A linear B-cell epitope on the class 3 outer-membrane protein of Neisseria meningitidis recognized after vaccination with the Norwegian group B outer-membrane vesicle vaccine. Microbiology 141:1593-1600. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources